Protein Acetylation-dependent Control of Metabolic Remodeling in Heart Failure with Preserved Ejection Fraction (HFpEF)
Protein Acetylation-dependent Control of Metabolic Remodeling in Heart Failure with Preserved Ejection Fraction (HFpEF)
批准号:
9540534
负责人:
Dan Tong
金额:
$6.96万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-04-01 至 2019-06-30
关键词:
3-Hydroxyacyl-CoA dehydrogenaseAcetylationAdultAttenuatedBiological AssayCardiacCardiac MyocytesCardiovascular ManifestationCardiovascular systemCharacteristicsCitric Acid CycleClinicalDataDeacetylaseDefectDiabetes MellitusDiseaseDistressEFRACEchocardiographyElectron TransportEnzymesExercise stress testFailureFunctional disorderFutureHealth ExpendituresHealthcareHeartHeart MitochondriaHeart failureHumanImmunoprecipitationImpairmentIn VitroLaboratoriesLinkMeasurementMeasuresMetabolicMetabolic ControlMetabolic DiseasesMetabolic syndromeMethodsMitochondriaMitochondrial ProteinsModelingMorbidity - disease rateMorphologyMusMyocardial dysfunctionMyocardiumNADHNicotinamide MononucleotideObesityOxidoreductaseOxygen ConsumptionPathogenesisPathway interactionsPatientsPerformancePharmacologyPhasePlayProcessProtein AcetylationProteinsRoleScienceSourceSyndromeTestingTherapeuticTrainingTreatment FailureWorkbaseclinical translationeffective therapyfatty acid oxidationheart functionhemodynamicsimprovedin vivoinsightmitochondrial dysfunctionmortalitymouse modelnoveltherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Proposal Summary
Heart failure with preserved ejection fraction (HFpEF) accounts for ≈50% of all patients with heart
failure, and is associated with significant morbidity, mortality and health care expenses. Yet no
effective treatment for HFpEF has been identified. Commonly coexisting with other metabolic
diseases, HFpEF is considered as the cardiovascular manifestation of a systemic metabolic
disturbance. However, little is known about its underlying mechanisms. Our laboratory recently
developed and validated a novel mouse model that faithfully recapitulates most clinical features
of human HFpEF. Using this model, we discovered significant myocardial mitochondrial morphology
changes indicating possible dysfunction, a potential common pathway linking metabolic distress with
cardiac dysfunction. Therefore, the current proposal aims to identify specific mitochondrial defects
and metabolic changes in HFpEF myocardium and their underlying mechanisms. Our preliminary
data suggest that HFpEF mitochondria harbor a specific defect in fatty acid oxidation (FAO),
which is accompanied by significant mitochondrial protein hyperacetylation. Further study is
proposed to test whether hyperacetylation of key FAO enzymes, a known mechanism that impairs
FAO in other metabolic diseases, also play a role in HFpEF. Given the fact that protein acetylation is
a reversible process, we will test both in vitro and in vivo whether pharmacological agents that
reverse protein hyperacetylaition attenuate mitochondrial dysfunction and improve cardiac function.
Collectively, these studies will provide important insights into the mitochondrial metabolic defects
characteristic of HFpEF. By focusing on reversible protein acetylation, the findings will have potential
for immediate clinical translation. Furthermore, this work will serve as a critical platform for future
mechanistic studies of HFpEF pathogenesis and for the next stages of my training.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein acetylation-dependent fatty acid metabolic dysfunction in HFpEF
-
批准号:10369549
-
项目类别:
-
资助金额:$14.77万
-
财政年份:2022
-
负责人:Dan Tong
-
依托单位:
Protein acetylation-dependent fatty acid metabolic dysfunction in HFpEF
-
批准号:10557911
-
项目类别:
-
资助金额:$14.77万
-
财政年份:2022
-
负责人:Dan Tong
-
依托单位:
海外基金